



Neurotech secures medical technology specialist Ashnev Medicals as distribution partner in India

*- Ashnev Medicals to exclusively distribute Mente Autism in India
- Initial product training to be followed by marketing activities in January 2018*

Perth, Australia & Malta – 18 January 2018 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions improving the lives of children with autism, has secured Ashnev Medicals (“Ashnev”) as its marketing and distribution partner in India.

Based in Kerala, India, Ashnev has over a decade of experience working with the latest technology in medical equipment, pharmaceutical products, health and rehabilitation diagnostics and treatments. Ashnev supplies products under various rental, retail and wholesale models, with more detail available on its website at the following link: www.ashnevmedicals.com.

Ashnev’s personnel will shortly undergo a period of product training, following which various marketing activities in Kerala, Cochin and Trichur will be launched.

Wolfgang Storf, CEO of Neurotech International, said: “This is another important milestone in our distribution partner expansion program. Ashnev Medicals have the credentials to be an impactful distribution partner for us in India, where we see massive market potential. We look forward to working with them to promote Mente Autism and continue our pursuit of growing adoption of the product.”

Dr Vinitha, CEO of Ashnev said: “We thank Neurotech for electing to work with us to represent the Mente Autism product in India. Given the quality of the product we are confident that our experience and network in the region will create very positive outcomes for both companies.”

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Neurotech International Ltd

ABN 73 610 205 402
Level 14, 191 St Georges Terrace
Perth, Western Australia 6060
www.neurotechinternational.com

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

For more information please contact:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420